FDA Fast-Tracks Lecanemab for Alzheimer ' s Disease FDA Fast-Tracks Lecanemab for Alzheimer ' s Disease

The FDA has granted breakthrough therapy designation to lecanemab (BAN2401), an investigational anti-amyloid beta protofibril antibody for the treatment of Alzheimer ' s disease.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Psychiatry News Source Type: news